Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Earnings Results, Misses Estimates By $1.43 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) released its earnings results on Monday. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43), FiscalAI reports. Supernus Pharmaceuticals had a positive return on equity of 13.07% and a negative net margin of 3.74%.The firm had revenue of $201.90 million during the quarter, compared to analysts’ expectations of $205.31 million.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $44.63 on Monday. Supernus Pharmaceuticals has a 1 year low of $32.83 and a 1 year high of $59.68. The company has a 50 day simple moving average of $46.27 and a two-hundred day simple moving average of $49.08. The firm has a market cap of $2.59 billion, a P/E ratio of -87.51, a price-to-earnings-growth ratio of 0.95 and a beta of 0.56.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Corient Private Wealth LLC bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $237,000. Invesco Ltd. boosted its holdings in shares of Supernus Pharmaceuticals by 9.4% during the 4th quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company’s stock valued at $19,669,000 after purchasing an additional 33,895 shares during the last quarter. Mackenzie Financial Corp purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $223,000. Zacks Investment Management purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $1,807,000. Finally, SummitTX Capital L.P. increased its holdings in shares of Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock worth $580,000 after purchasing an additional 303 shares during the last quarter.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of recent analyst reports. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.